Pharmacogenomics in Stroke: Feasibility of CYP2C19 Testing (NCT06943586) | Clinical Trial Compass
RecruitingNot Applicable
Pharmacogenomics in Stroke: Feasibility of CYP2C19 Testing
United States200 participantsStarted 2025-04-09
Plain-language summary
The purpose of this research study is to explore whether genetic testing can offer a personalized and timely approach to assist physicians in making more informed medication decisions for stroke or high-risk transient ischemic attack (TIA) patients during their hospital stay.
Who can participate
Age range
18 Years – 89 Years
Sex
ALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion Criteria:
* Patients 18-89 years of age
* admitted to University of Alabama at Birmingham (UAB) main hospital with symptoms or signs of minor ischemic stroke, or high risk TIA
* eligible to receive dual antiplatelet load (presented to the hospital within 66 hours of last known well)
Exclusion Criteria:
* diagnosis of atrial fibrillation, valvular heart disease, index stroke due to known hypercoagulability (subset of other determined etiology) or large vessel disease (culprit vessel stenosis of ≥50%)
* prescribed anticoagulation prior to stroke
* treated with intravenous thrombolysis
* treated with mechanical thrombectomy
* missing NIH Stroke Scale score
Questions worth asking your doctor
Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.
1This study focuses on returning CYP2C19 genetic test results to stroke and TIA patients — can you explain what CYP2C19 is and why knowing my genetic variant might matter for the blood thinners I'm currently being prescribed?
2Since this trial is listed as Phase NA and its main goal is to test whether it's *feasible* to deliver genetic test results to patients like me — rather than to directly test a new treatment — what would actually change about my care, if anything, based on what the genetic test shows?
3The trial is actively recruiting right now — how quickly would I receive my CYP2C19 results, and given that I just had a stroke or TIA, is the timing of getting those results soon enough to influence my treatment decisions?
4Are there standard-of-care options where my doctor could already order CYP2C19 testing outside of this trial, and if so, what would be the main reason to join this study instead of just getting the test done on my own?
5If the genetic results suggest I process certain medications differently, would the study team actually adjust my medication, or would that decision still rest entirely with my treating physician?
Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.
Questions for the trial coordinator
The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.
1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?
A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.
What they're measuring
1
Stroke participant feasibility of return of CYP2C19 genetic testing results